INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET
Company Participants
David Moss - Chief Financial Officer
RJ Tesi - Chief Executive Officer & Chief Medical Officer
Conference Call Participants
Joel Beatty - Baird
Operator
Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is my pleasure to introduce to you Mr. David Moss, CFO of INmune Bio. David, thank you. The floor is yours.
David Moss
Thank you, John, and good afternoon, everybody. We thank you for joining us for the call for Immune Bio's second quarter 2023 financial results. With me on the call, actually sitting right next to me is Dr. RJ Tesi, CEO of Immu Bio, who will provide an update on our two platforms, XPro and INKmune.
Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.
Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filing with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as of the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances.
With that behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of Immuno Bio. RJ?
RJ Tesi
Thank you, David, and thank you, everyone for joining the call. As usual, I will arrange my remarks to highlight the key takeaways for the second quarter and subsequent period, and provide updates on our platform programs.
I will start by reviewing our developments with XPro and INKmune before I pass it back to David to discuss financial results and provide an update on upcoming and new milestones. We will then move to Q&A.